Compare Stocks: COAG, TGTX, ALKS, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$47.41 -3.0%	$50.91	$25.17 ▼ $55.67	$7.95B	0.34	1.37 million shs	1.43 million shs
COAG Hemab Therapeutics	$44.84 -9.4%	$43.76	$23.00 ▼ $55.42	$2.09B	N/A	341,259 shs	260,078 shs
SYRE Spyre Therapeutics	$90.36 -3.5%	$98.43	$14.51 ▼ $110.18	$7.95B	3.03	934,375 shs	1.27 million shs
TGTX TG Therapeutics	$53.93 -3.2%	$53.37	$26.76 ▼ $59.30	$8.26B	1.62	2.28 million shs	1.03 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-1.90%	-5.24%	+12.37%	+62.09%
COAG Hemab Therapeutics	0.00%	-8.79%	-5.54%	+57.33%	+4,483,999,900.00%
SYRE Spyre Therapeutics	0.00%	-15.15%	-10.98%	+22.94%	+427.19%
TGTX TG Therapeutics	0.00%	-0.63%	+0.75%	+42.15%	+88.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$47.41 -3.0%	$50.91	$25.17 ▼ $55.67	$7.95B	0.34	1.37 million shs	1.43 million shs
COAG Hemab Therapeutics	$44.84 -9.4%	$43.76	$23.00 ▼ $55.42	$2.09B	N/A	341,259 shs	260,078 shs
SYRE Spyre Therapeutics	$90.36 -3.5%	$98.43	$14.51 ▼ $110.18	$7.95B	3.03	934,375 shs	1.27 million shs
TGTX TG Therapeutics	$53.93 -3.2%	$53.37	$26.76 ▼ $59.30	$8.26B	1.62	2.28 million shs	1.03 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-1.90%	-5.24%	+12.37%	+62.09%
COAG Hemab Therapeutics	0.00%	-8.79%	-5.54%	+57.33%	+4,483,999,900.00%
SYRE Spyre Therapeutics	0.00%	-15.15%	-10.98%	+22.94%	+427.19%
TGTX TG Therapeutics	0.00%	-0.63%	+0.75%	+42.15%	+88.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	15.09% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	14.63% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	21.39% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	16.82% Upside

Current Analyst Ratings Breakdown

Latest COAG, TGTX, ALKS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/13/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/12/2026	COAG Hemab Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$55.00 ➝ $64.00
8/11/2026	COAG Hemab Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $60.00
8/11/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$112.00 ➝ $132.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/5/2026	SYRE Spyre Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
8/5/2026	SYRE Spyre Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$90.00 ➝ $115.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	5.39	$1.67 per share	28.32	$10.78 per share	4.40
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	$9.72 per share	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$10.86 per share	N/A
TGTX TG Therapeutics	$799.54M	10.32	$2.80 per share	19.25	$3.95 per share	13.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	124.77	197.54	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.68	20.35	2.31	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest COAG, TGTX, ALKS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
COAG Hemab Therapeutics	N/A	35.85	35.85
SYRE Spyre Therapeutics	N/A	18.53	18.53
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
COAG Hemab Therapeutics	N/A
SYRE Spyre Therapeutics	80.39%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
COAG Hemab Therapeutics	N/A
SYRE Spyre Therapeutics	15.69%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
COAG Hemab Therapeutics	72	46.71 million	N/A	N/A
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

COAG, TGTX, ALKS, and SYRE Headlines

Recent News About These Companies

Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX

August 30 at 5:11 AM | marketbeat.com

Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 29 at 3:05 AM | marketbeat.com

Bank of New York Mellon Corp Takes $49.47 Million Position in TG Therapeutics, Inc. $TGTX

August 28 at 3:04 AM | marketbeat.com

PDT Partners LLC Acquires Shares of 41,585 TG Therapeutics, Inc. $TGTX

August 27 at 5:21 AM | marketbeat.com

TG Therapeutics Tests BRIUMVI in Schizophrenia: A New Angle for Long-Term Growth

August 26, 2026 | tipranks.com

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)

August 26, 2026 | seekingalpha.com

Castleark Management LLC Buys Shares of 150,990 TG Therapeutics, Inc. $TGTX

August 26, 2026 | marketbeat.com

TGTX stock outperforms 95% of stocks. Here's why.

August 24, 2026 | msn.com

Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX

August 23, 2026 | marketbeat.com

235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG

August 23, 2026 | marketbeat.com

Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

August 23, 2026 | americanbankingnews.com

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

August 22, 2026 | seekingalpha.com

BlackRock Inc. Takes Position in TG Therapeutics, Inc. $TGTX

August 22, 2026 | marketbeat.com

TGTX stock alert: What to know as takeover rumors swirl around TG Therapeutics

August 21, 2026 | msn.com

TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher - Should You Buy?

August 21, 2026 | marketbeat.com

TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

August 21, 2026 | marketbeat.com

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

August 17, 2026 | marketbeat.com

Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

COAG, TGTX, ALKS, and SYRE Company Descriptions

Alkermes NASDAQ:ALKS

$47.41 -1.49 (-3.05%)

As of 08/28/2026 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Hemab Therapeutics NASDAQ:COAG

$44.84 -4.65 (-9.40%)

As of 08/28/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Spyre Therapeutics NASDAQ:SYRE

$90.36 -3.25 (-3.47%)

As of 08/28/2026 04:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$53.93 -1.79 (-3.21%)

As of 08/28/2026 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, TGTX, ALKS, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, TGTX, ALKS, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, TGTX, ALKS, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

COAG, TGTX, ALKS, and SYRE Company Descriptions

Alkermes NASDAQ:ALKS

Hemab Therapeutics NASDAQ:COAG

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COAG, TGTX, ALKS, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COAG, TGTX, ALKS, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COAG, TGTX, ALKS, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

COAG, TGTX, ALKS, and SYRE Company Descriptions

Alkermes NASDAQ:ALKS

Hemab Therapeutics NASDAQ:COAG

Spyre Therapeutics NASDAQ:SYRE

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools